Iran University of Medical Sciences   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Tehran Iran (Islamic Republic of) (1974)

Organization Overview

First Clinical Trial
2006
NCT00564252
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran | Department Of Pediatric Nephrology and Dialysis, Ali aghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran | Department of Pharmacology and Toxicology, Faculty of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, Iran | Department of Psychiatry and Mental Health Research Center, Iran University of Medical Sciences | endocrine and metabolism centre of Iran University of Medical Sciences | Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran. | Firuzgar hospital affiliated to Iran University of Medical Sciences | Iran University of Medical Sciences | Iran University of Medical Sciences(IUMS)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 2)

Dermatitis (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Retinopathy (Phase 1)

Dissociative Disorders (Phase 1)

Glomerulosclerosis, Focal Segmental (Phase 1)

Inflammation (Phase 3)

Nephrosis (Phase 1)

Nephrotic Syndrome (Phase 1)

Optic Nerve Diseases (Phase 3)

Optic Nerve Injuries (Phase 3)

Orbital Pseudotumor (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Radiodermatitis (Phase 2)

Retinal Detachment (Phase 1)

Retinal Diseases (Phase 1)

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 16